Topical vs Oral Finasteride: What the Evidence Actually Shows
Last reviewed on 19 July 2026. We review our treatment guides every six months to keep them accurate.
Finasteride is the best known medicine for male pattern hair loss, and it now comes in two very different forms. Oral finasteride is the 1mg tablet taken once a day. Topical finasteride is a solution, spray or gel applied to the scalp, and it is usually promoted on the promise of the same benefit with fewer side effects. This guide sets out the difference between them, what the research actually shows, how the side effects compare, what switching from oral to topical involves, whether you can take both, and where topical finasteride stands in the UK. It is general information rather than medical advice, so please speak to a doctor or dermatologist about your own situation.
One point is worth making before anything else, because a great many pages get it wrong. In the UK, oral finasteride 1mg is a licensed medicine for male pattern hair loss. Topical finasteride is not a licensed UK medicine for anything. That single difference runs through everything below.
For the current UK safety position on this class of medicine, the medicines regulator, the MHRA, publishes a drug safety update covering finasteride and dutasteride. It is the regulator's own page and is updated when the advice changes, so it stays current between our own reviews.
What is the difference between topical and oral finasteride?
Both forms contain the same drug and work in the same way. Finasteride is a 5-alpha-reductase inhibitor: it blocks the enzyme that converts testosterone into dihydrotestosterone (DHT). In men who are genetically susceptible, DHT binds to receptors in scalp hair follicles and gradually shrinks them, a process called miniaturisation, so the hairs they produce become finer and shorter. Lowering DHT is intended to slow that process and, in some men, allow a degree of regrowth where follicles are still active. Any DHT blocker, topical or oral, works only while it is being used.
The practical differences are these:
How it is used. Oral finasteride is one 1mg tablet a day. Topical finasteride is applied to the scalp, as a spray, solution or gel, once or twice daily depending on the product. There is no single standard topical strength or regimen, which is part of the problem discussed below.
How much reaches the bloodstream. This is the real difference. The tablet is absorbed through the gut and acts throughout the body. Topical finasteride is intended to act mainly on the scalp, and it does put far less drug into the blood. It does not, however, stay in the scalp.
Licensing. The tablet has been assessed and approved by the UK regulator for this use. Topical finasteride has not.
Depth of evidence. Oral finasteride has been studied in large trials over five to ten years. The topical evidence is smaller, shorter and much of it is very recent.
Is topical finasteride available in the UK?
It can be obtained, but not as a licensed medicine. Finasteride tablets hold UK marketing authorisations at 1mg for male pattern hair loss in men and at 5mg for an enlarged prostate. Every finasteride product currently listed on the electronic Medicines Compendium, the UK register of approved product information, is a tablet. The NHS page on finasteride likewise describes it only as tablets, and notes that for hair loss it is available on private prescription only, not on the NHS.
Topical finasteride therefore reaches UK patients as an unlicensed medicine, either compounded by a pharmacy or imported, and supplied against a private prescription under what the MHRA calls the specials regime. That is lawful. It is not unusual in dermatology. But it does mean the product has not been assessed by the UK regulator for safety, effectiveness or quality, it does not come with UK-approved product information, and the prescriber carries more responsibility for the decision than when prescribing within a licence.
It is worth being precise about what unlicensed means here, because it is a UK statement rather than a verdict on the science. Finasteride cutaneous spray solutions are authorised in several other European countries for early male pattern hair loss. The UK simply is not one of them at the time of this review.
What the evidence on topical finasteride actually shows
The argument for topical finasteride is straightforward and reasonable: inhibit 5-alpha reductase in the scalp, where it matters for hair, while putting less drug into the rest of the body, and you might keep the benefit while reducing the systemic side effects. The question is whether that is what happens.
The main trial
The strongest evidence is a phase III randomised, double-blind trial published in 2022. It enrolled 458 men with male pattern hair loss at 45 sites across five European countries and compared a 0.25% topical finasteride spray, a dummy spray and the oral 1mg tablet over 24 weeks. Two findings matter.
On hair count, topical finasteride worked. The average gain in the target area at 24 weeks was 20.2 hairs with topical finasteride against 6.7 with placebo, a statistically significant difference, and 21.1 hairs with the oral tablet. In other words topical was clearly better than nothing and numerically close to the tablet over six months.
On absorption, the result is the one people rarely quote. Topical finasteride lowered DHT in the blood. Serum DHT fell by about 35% from baseline in the topical group, compared with about 56% in the oral group and no change on placebo. Peak finasteride levels in plasma were more than a hundred times lower with the spray than with the tablet, but they were not zero, and the fall in circulating DHT was real and statistically significant. Topical finasteride is absorbed. It is not confined to the scalp.
The trial has limits worth knowing. It ran for 24 weeks, which is short for a treatment taken for years. Only about 55% of those randomised had hair counts that could be evaluated. It was funded by the companies developing the product. And it tested one specific formulation at one strength, not the varied compounded products sold elsewhere.
Absorption depends on the product
A 2022 review of the topical finasteride literature reached the same conclusion and added an important qualifier: topical finasteride reduces both scalp and plasma DHT, and in one short pharmacodynamic study a twice-daily 0.25% topical solution suppressed plasma DHT to a similar degree as the 1mg tablet. How much reaches the bloodstream depends on the strength, the volume, how often it is applied and how the product is made. With an unlicensed compounded product, none of that is standardised, so it is not possible to assume any particular product behaves like the one used in the trial.
Topical versus oral finasteride: side effects compared
This is the reason most people are reading this page, so it deserves a careful answer rather than a reassuring one.
Topical finasteride adds side effects the tablet does not have, all at the application site: itching, burning or stinging, redness, dryness and scaling, and contact dermatitis. In the phase III trial, local tolerability was good and skin reactions were uncommon, but they are the trade-off for putting a medicine on the scalp twice a day.
On the systemic side effects, the ones people are trying to avoid, the honest position has three parts.
Lower exposure is real. Less finasteride in the blood and a smaller fall in circulating DHT plausibly mean a lower chance of the DHT-related effects, which is what the trial authors concluded. In the trial itself, treatment-related sexual side effects were reported by 2.8% on topical, 3.3% on placebo and 4.8% on the tablet, and there was no significant difference between groups on a standardised sexual function questionnaire.
The evidence is weaker than that sounds. Those numbers come from a single 24-week trial with a few hundred men. A study of that size and length cannot rule out uncommon or delayed effects, and it was not designed to. Absence of a signal over six months is not proof of safety over six years.
The class warnings still apply. Because topical finasteride is absorbed and does lower DHT in the blood, there is no basis for saying it avoids the risks that apply to the tablet. It should not be described as a safe version of finasteride.
The MHRA position
In April 2024 the MHRA introduced patient alert cards for finasteride, highlighting psychiatric and sexual side effects. On 11 May 2026 it strengthened the warnings further, for finasteride and, as a precaution, for the related medicine dutasteride. The current position is that finasteride is associated with depression, suicidal ideation and sexual dysfunction which may persist after treatment is stopped, and that sexual dysfunction may itself contribute to mood disorders. Anyone taking finasteride 1mg who develops depression or suicidal thoughts is advised to stop and contact their doctor as soon as possible. You can read the current advice in the MHRA drug safety update.
There is a wrinkle here that applies specifically to topical products. Those warnings and the patient card are attached to licensed finasteride tablets. An unlicensed topical supplied on a private prescription does not carry UK-approved product information or a patient alert card, so the safety information a patient receives depends entirely on the prescriber.
That is not a theoretical concern. In 2025 the American regulator, the FDA, issued an alert about compounded topical finasteride after 32 adverse event reports between 2019 and 2024. The reported effects, erectile dysfunction, reduced libido, low mood, anxiety, insomnia and difficulty concentrating, were the same ones reported with the tablets, most were said to have persisted after stopping, and the regulator noted that some patients had been told there was no risk because the product was topical. Its plain statement is worth repeating: absorption of finasteride through the skin into the bloodstream is expected.
Switching from oral to topical finasteride
This is the most common question on this subject, and the honest answer is less tidy than most pages make it.
People usually want to switch for one of two reasons: they are getting side effects on the tablet and hope a topical will let them keep treating hair loss, or they are doing well but would rather not have a daily systemic medicine. Both are understandable. Neither has a protocol behind it.
There is no established switching regimen in the published evidence. The trials compared topical against placebo and against the tablet in men starting treatment; none of them tested moving people from one to the other, so there is no evidence-based answer on what strength to switch to, whether to taper or stop the tablet outright, or how to tell early whether the topical is holding the result. Anyone offering you a confident protocol is going beyond what has been studied.
Two practical points are worth carrying into that conversation with a prescriber. First, the benefit of any DHT blocker lasts only while it is used, so if the topical does not hold your result, hair gained on the tablet can gradually be lost, and that loss is not always recoverable. Second, if you are switching because of side effects you believe are caused by finasteride, a topical still delivers finasteride and still lowers DHT in your blood, so it is not guaranteed to resolve them. Whether to switch, and how, is a decision for your doctor or dermatologist, who can weigh your own history.
Can you take oral and topical finasteride together?
You can, in the sense that it is physically possible and some prescribers do it, but there is no good evidence supporting routine combination and a clear reason for caution. Both forms deliver the same drug and both lower DHT in the blood, so using them together increases your total exposure rather than targeting the scalp more cleverly. No trial has shown that combining them produces better hair outcomes than the tablet alone, and adding a second source of finasteride is the opposite of the reason most people are interested in topical treatment in the first place. If it has been suggested to you, ask what it is expected to add and why. It is a prescriber's decision, not a self-directed one.
Combining topical finasteride with minoxidil is a different question, because minoxidil is not a DHT blocker and works by another route. Some topical products are compounded with both. That is still a clinician's call, but it does not carry the same double-dosing objection.
Pregnancy, partners and the transfer question
This is the point most comparison pages miss, and it is one where topical is arguably the more difficult formulation, not the safer one.
Because DHT is needed for the normal development of a male baby, 5-alpha-reductase inhibitors can interfere with that development and must not be taken by anyone who is pregnant or who might become pregnant. With tablets, the practical rule is simple: the coating prevents contact during normal handling, and a woman who is or could be pregnant should not handle crushed or broken tablets. This is covered in more detail in our guides on DHT blockers for women and on finasteride when trying for a baby.
A topical has no coating. It sits on the scalp, and it can be transferred by touch, by a pillow, or by someone else handling the bottle. The FDA specifically flags a greater potential risk of inadvertent exposure to others, particularly women, through transfer of the applied product. This does not make topical finasteride unusable in a household with a pregnant partner or young children, but it is a real consideration that ought to be raised before starting, and it is a question worth putting directly to whoever is prescribing it.
Buying topical finasteride in the UK
Searches for the best topical finasteride in the UK are common, and the honest answer is that there is no licensed UK product to point to, so there is no regulator-approved standard against which one product can be called better than another. Strengths, vehicles and dosing instructions differ between compounders, and, as above, how much reaches the bloodstream differs with them.
What matters more than the brand is the route. Finasteride in any form is a prescription-only medicine in the UK. It should come from a prescriber who has taken a history, who tells you about the psychiatric and sexual side effects before you start rather than after, and who will review you. A GP, a dermatologist or a GPhC-registered pharmacy offering a regulated prescribing service are the appropriate routes. Websites selling finasteride without a genuine consultation, or shipping it from abroad without a prescription, sit outside that system entirely, and with an unlicensed compounded product there is no independent check on what is actually in the bottle.
What else has evidence
If the aim is to treat hair loss without an oral DHT blocker, the treatment with the strongest independent evidence is topical minoxidil, which is licensed in the UK for pattern hair loss, works by a different mechanism and does not act on DHT at all. It is not a like-for-like replacement, since it does not address the hormonal driver, but it is the better established topical option. Supplements marketed as natural DHT blockers are a much weaker proposition, which we cover in our guide to natural DHT blockers.
Frequently asked questions
What is the difference between topical and oral finasteride?
Both contain the same drug and both block the enzyme that makes DHT. Oral finasteride is a 1mg tablet taken daily and acts throughout the body. Topical finasteride is applied to the scalp and puts far less of the drug into the bloodstream, though not none. The other difference is regulatory: in the UK the tablet is a licensed medicine for male pattern hair loss and the topical is not, so any topical is supplied as an unlicensed product on a private prescription.
Can I switch from oral to topical finasteride?
It is possible, and it is a decision for your prescriber rather than something to do on your own. There is no established switching protocol in the evidence, because the trials compared the two treatments rather than testing a change from one to the other. The two things to weigh are that the benefit of finasteride only lasts while it is used, so hair gained on the tablet can be lost if the topical does not hold it, and that a topical still delivers finasteride, so it may not resolve side effects you attribute to the tablet.
Does topical finasteride have fewer side effects?
It has fewer of the systemic ones in the short-term evidence available, and it adds local ones such as itching, burning, redness and contact dermatitis. In the main trial, sexual side effects were reported by 2.8% on topical against 4.8% on the tablet, but that was a single 24-week study, too small and too short to rule out uncommon or delayed effects. Because topical finasteride is absorbed and does lower DHT in the blood, it should not be treated as a side-effect-free version, and the MHRA warnings on depression, suicidal thoughts and sexual dysfunction remain relevant. Our guide on finasteride sexual side effects covers how common they are and whether they last.
Can you take oral and topical finasteride together?
There is no good evidence that routinely combining them works better than the tablet alone, and because both put finasteride into your bloodstream, taking both increases your total exposure. That runs against the usual reason for choosing a topical. If a prescriber suggests it, ask what it is intended to achieve. It is not something to add by yourself.
Is topical finasteride available in the UK?
Not as a licensed medicine. Every finasteride product approved in the UK is a tablet, and topical finasteride is supplied as an unlicensed compounded or imported product on a private prescription. That is lawful, but it means the product has not been assessed by the MHRA and does not come with UK-approved product information or a patient alert card. Finasteride sprays are licensed in some other European countries, just not here at present.
The bottom line
Topical and oral finasteride are the same drug delivered two ways. The tablet is licensed in the UK, has decades of trial data behind it, and acts throughout the body. Topical finasteride has one good randomised trial showing it improves hair count and comes close to the tablet over six months, with far lower drug levels in the blood, which is a genuine advantage. What it is not is a version of finasteride without systemic effects: it is absorbed, it lowers DHT in the bloodstream, and the same class warnings apply. In the UK it remains unlicensed, so it comes without the assessment, the standardisation and the patient safety card attached to the tablet. If you are weighing one against the other, or thinking about switching, that is a conversation to have with a doctor or dermatologist who can look at your own history, not a decision to make from a product page.
Get back to Great Hair
in 3 Easy Steps:
01
Arrange Free Consultation
Speak to one of our specialist consultants for expert advice on our range of different hair loss treatments
02
Book Your Procedure
Place a deposit to reserve a time slot at one of the My Hair UK clinics across the UK
03
Attend Your Surgery
Arrive on the day and our specialist surgical team will look after your every need
